Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: Evidence from US community oncology clinics

Medical Oncology

Volumn 29, Issue 2, 2012, Pages 786-794

  Feinberg, Bruce A ^a,b   Jolly, Pradeep ^c   Wang, Si Tien ^d   Fortner, Barry ^b   Scott, Jeffrey ^b   Gilmore, James ^c   Neary, Maureen P ^e   Duh, Mei Sheng ^d  

^a CARDINAL HEALTH   (United States)

^b P4 Healthcare ^*  (United States)

^c Georgia Cancer Specialists   (United States)

^d ANALYSIS GROUP   (United States)

^e GLAXOSMITHKLINE   (United States)

Author keywords

Angiogenesis inhibitor; Renal cell carcinoma; Safety

Indexed keywords

SORAFENIB; SUNITINIB; ANGIOGENESIS INHIBITOR; BENZENESULFONIC ACID DERIVATIVE; INDOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER CENTER; DRUG EFFICACY; DRUG SAFETY; FATIGUE; HUMAN; KIDNEY CARCINOMA; LUNG METASTASIS; MAJOR CLINICAL STUDY; MEDICAL PRACTICE; OPEN STUDY; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; TREATMENT DURATION; UNITED STATES; WEAKNESS; ADULT; AGED; CANCER STAGING; CLINICAL PRACTICE; COMMUNITY CARE; FEMALE; FOLLOW UP; KIDNEY TUMOR; MALE; MEDICAL RECORD; METASTASIS; MIDDLE AGED; MORTALITY; ORGANIZATION AND MANAGEMENT; OUTCOME ASSESSMENT; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; BENZENESULFONATES; CANCER CARE FACILITIES; CARCINOMA, RENAL CELL; COMMUNITY HEALTH SERVICES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MEDICAL RECORDS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; OUTCOME ASSESSMENT (HEALTH CARE); PHYSICIAN'S PRACTICE PATTERNS; PYRIDINES; PYRROLES; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84866294721     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-9922-z     Document Type: Article

References (17)

1. Rohrmann K, Staehler M, Haseke N, et al. Immunotherapy in metastatic renal cell carcinoma. World J Urol. 2005;23:196-201.
2. Parmar S, Rademaker AW, Fung BB, et al. High dose IL-2 is associated with durable disease free survival and clinically important improvement in overall survival in metastatic renal cell cancer. Proc Am Soc Clin Oncol 2003;22:(abstr 1630).
3. Motzer RJ, Mazumdar M, Bacik J, et al. Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol. 2000;18:1928-35.
4. Haferkamp A, Hofenfellner M. Medical treatment options in patients with metastatic renal cell carcinoma. Nephrol Dial Transplant. 2007;22:996-9.
5. Kapoor A, Figlin R. Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma. Cancer. 2009;115:3618-30.
6. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. New Engl J Med. 2007;356(2): 125-34.
7. Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. J Clin Oncol. 2009;27:3312-8.
8. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alpha in metastatic renal cell carcinoma. New Engl J Med. 2007;356(2):115-24.
9. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009; 27(22):3584-90.
10. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New Engl J Med. 2007;356(22):2271-81.
11. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomized, double-blind phase III trial. Lancet. 2007; 370(9605):2103-11.
12. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061-8.
13. Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 2009;10(8):757-63.
14. Knox JJ, Figlin RA, Stadler WM, et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial in North America: safety and efficacy. J Clin Oncol 2007 ASCO Annu Meet Proc Part I. 2007;25(18S) (June 20 Supplement):5011.
15. Choueiri TK, Duh MS, Clement J, et al. Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review. BJU Int. 2010;105(9):1247-54.
16. Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. URL: http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ctcaev3. pdf [accessed: 27 Aug 2008].
17. Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol. 2010;66(2):357-71.